(Q29619805)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

30 April 2017

0 references

0 references

0 references

1 reference

Feld JJ

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

30 April 2017

Hoofnagle JH

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

18 August 2005

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

30 April 2017

volume

436

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

30 April 2017

issue

7053

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

30 April 2017

page(s)

967-72

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Human interferons alpha, beta and omega

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

1 May 2017

Viruses and interferons

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Lambda interferon inhibits hepatitis B and C virus replication

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Efficient initiation of HCV RNA replication in cell culture

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Effect of alpha interferon on the hepatitis C virus replicon

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Viruses and interferon: a fight for supremacy

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Analysis of successful immune responses in persons infected with hepatitis C virus

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Immunology of hepatitis B virus and hepatitis C virus infection

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

RNA virus error catastrophe: direct molecular test by using ribavirin

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Robust hepatitis C virus infection in vitro

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Complete replication of hepatitis C virus in cell culture

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Viral kinetics of hepatitis C: new insights and remaining limitations

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Pilot study of interferon gamma for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Effector genes of interferon action against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Mechanism of the interferon alpha response against hepatitis C virus replicons

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

The interferon sensitivity determining region: all hepatitis C virus isolates are not the same

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Hepatitis C virus: evasion of the interferon-induced antiviral response.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Effects of antiviral therapy on the cellular immune response in acute hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Prolonged therapy of chronic hepatitis C with ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Antiviral action of ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

Deoxycholic acid activates protein kinase C and phospholipase C via increased Ca2+ entry at plasma membrane.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04082

7 January 2021

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16107837

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

421143

Dimensions Publication ID

1037596254

0 references

OpenCitations bibliographic resource ID

421143

1 reference